Kidney Dysfunction in HIV-Positive Patients on HAART In a Nigerian Tertiary Hospital: A Comparative Study https://doi.org/10.60787/NMJ-63-6-169
Main Article Content
Keywords
HAART, tenofovir,, β₂-microglobulin, kidney dysfunction, tubular dysfunction
Abstract
Background: There has been improvement in the overall outcomes of people living with human immunodeficiency virus (PLWHIV) following the advent and use of highly active antiretroviral therapy (HAART). However, there is an increased risk of nephrotoxicity from using HAART in PLWHIV as their life expectancy improves. This study assessed and compared renal dysfunction among PLWHIV on tenofovir-based and non-tenofovir-based HAART.
Methodology: This comparative cross-sectional study determined and compared glomerular and tubular dysfunction among PLWHIV on tenofovir-based and non-tenofovir-based HAART. Urine beta2-microglobulin, fractional excretion of bicarbonate, uric acid, and Phosphate were used to assess proximal tubular function. The modification of diet in renal disease (MDRD) formula was used to estimate the glomerular filtration rate (eGFR).
Result: There were 120 participants with a mean age of 42.2 ±9.2 years. Sixty participants were on tenofovir-based HAART, and 60 were on non-tenofovir-based HAART. The overall prevalence of proximal renal tubular dysfunction among PLWHIV on HAART was 9.1%. The proximal renal tubular dysfunction prevalence was higher in the tenofovir-based group (15.0%vs3.3% P= 0.01). The mean urine β₂ MG level was higher in the tenofovir-based HAART group (0.21±0.15ug/ml vs 0.14±0.12ug/ml; P= 0.01). The mean eGFR was lower in the tenofovir-based HAART group (86.99±18.51mls/min/1.73m² vs 99.59±34.48mls/min/1.73m²; P=0.01).
Conclusion: Tenofovir-based HAART was associated with a significant decrease in GFR and proximal renal tubular dysfunction compared to non-tenofovir-based HAART. Those on tenofovir should be regularly monitored with markers of tubular dysfunction.
References
2.Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Research and Treatment. 2011. Accessed on August 8, 2022. Available from: https://doi.org/10.1155/2011/562790
3.Nelson M, Azwa A, Sokwala A, Harania RS, S tebbing J. Fanconi syndrome and lactic acidosisassociated with stavudine and lamivudinetherapy. AIDS.2008;22:1374–6.
4.Ngige E, Aboje S, Oloyede Y, Alonge B,Anyaike C, Asadu E et al. National Guidelines for HIV Prevention Treatment and Care 2016. Accessed on 8th August, 2022.Available from: http://apps.who.int/medicinedocs/documents/s23252en/s23252enpdf
5.Jimenez-Nacher I, Garcia B, Barreiro P, Rodriguez-Novoa S, Morello J, Gonzalez-Lahoz J,et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother.2008;62:816–22.
6.Nishijima T, Komatsu H, Higasa K, Takano M, Tsuchiya K, Hayashida T, et al. Single Nucleotide Polymorphisms in ABCC2 Associate with Tenofovir-Induced Kidney Tubular Dysfunction in Japanese Patients With HIV-1 Infection: A Pharmacogenetic Study. Clin Infect Dis. 2012;55:1558–67.
7.Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V, et al.Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infectedpatients.PLoS One. 2014;9:e92717
8.Crum-Cianflone N, Ganesan A, Teneza-Mora N, Riddle M, Medina S, Barahona I, et al. Prevalence and Factors Associated with Renal Dysfunction Among HIV-Infected Patients. AIDS Patient Care STDS. 2010; 24(6):353–60.
9.Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.Clin InfectDis. 2006;42:283–90.
10.Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009; 23:689-96.
11.Dauchy FA, Lawson-Ayayi S, de La Faille R, Bonnet F, Rigothier C, Mehsen N, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kid Int. 2011; 80:302-9.
12.Casado JL, Bañón S, Santiuste C, Serna J, Guzman P, Tenorio M et al. Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir. AIDS. 2016; 30:231-9
13.Ezinga M, Wetzels JF, Bosch ME, van der Ven AJ, Burger DM. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration . Antivir Ther.2014;19:765-71
14.Villa G, Phillips RO, Smith C, Stockdale AJ, Beloukas A, Appiah LT et al. Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV positive adults in Ghana. J Infect. 2018; 76:515-21.
15.Rodríguez-Nóvoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello, et al. Predictorsof kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009; 48:e108-16.
16.Chadwick DR, Sarfo FS, Kirk ES, Owusu D, Bedu-Addo G, Parris V, et al. tenofovir is associated with increased tubular proteinuria and asymptomatic renal tubular dysfunction in Ghana. BMC Nephrol. 2015; 16:195. doi: 10.1186/s12882-015-0192-4.
17.Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J ClinPharmacol. 2014 Sep;70:1029-40
18.Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013; 35:121-126.
19.Wantakisha E, Munkonbwe D, Tumba T, Michelo C. Incidence and association of renal dysfunction with a long term Tenofovir-based therapy among HIV-positive naïve cohort atRonald Ross Hospital. PAMJ-Clinical Medici ne.2020;3: 48:10.11604/pamj cm.2020.3.48.21115
20.Abefe SA, Abiola AF, Olubunmi AA, Adewale A. Utility of predicted creatinine clearanceusing MDRD formula compared with other predictive formulas in Nigerian patients. SaudiJ Kidney Dis Transpl. 2009;20:86-90.
21.Simkin PA, Hoover PL, Paxson CS, Wilson WF. Uric acid excretion: quantitative assessment from spot, mid-morning serum and urine samples. Ann Intern Med.1979; 91:44–7.
22.Tourret J, Deray G, Isnard-Bagnis C. Tenofovir Effect on the Kidneys of HIV-InfectedPatients: A Double-Edged Sword? J Am SocNephrol. 2013;24:1519-1527
23.Côté HCF, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther. 2006; 11:79–86
24.De Beaudrap P, Diallo MB, Landman R, Guèye NF, Ndiaye I, Diouf A, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses. 2010;26:1221-1227.
25.Mtisi TJ, Ndhlovu CE, Maponga CC, Morse GD. Tenofovir-associated kidney disease in Africans: a systematic review. AIDS Res Ther. 2019; 16:1-6.
26.Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019;33:1455-1465.
27.Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel pro-drug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016; 125:63-70.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.